Holen Sie sich die Stockscreener-App
3.51
2.23%
-0.08
Schlusskurs vom Vortag:
$3.59
Offen:
$3.4217
24-Stunden-Volumen:
43,892
Relative Volume:
2.12
Marktkapitalisierung:
$11.29M
Einnahmen:
Nettoeinkommen (Verlust:
$-37.68M
KGV:
-0.2965
EPS:
-11.8364
Netto-Cashflow:
$-30.65M
1W Leistung:
-2.50%
1M Leistung:
-29.09%
6M Leistung:
-42.74%
1J Leistung:
-57.17%
1-Tages-Spanne:
$3.4217
$3.86
1-Wochen-Bereich:
$3.37
$3.86
52-Wochen-Spanne:
$3.29
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
3.51 | 11.29M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2026-04-21 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-04-21 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-03-31 | Eingeleitet | Oppenheimer | Outperform |
| 2026-02-10 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
EQUITY ALERT: The M&A Class Action Firm Is Investigating the Merger -- UTZ, SAFT, PASG and FNWDIS IT A FAIR DEAL FOR YOU? - PR Newswire
Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE - StreetInsider
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Passage Bio amends merger terms: what it means for Passage Bio stock - AD HOC NEWS
$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD - GlobeNewswire Inc.
Passage Bio outlines USD 100.0 million financing for Passage Bio stock - ad-hoc-news.de
About $100M in financing is expected for Passage Bio (PASG)'s Remix merger, dividing ownership three ways. - Stock Titan
How Low Will Passage (PASG) Go After -0.96% Sell-Off? 2026-09-29Merger Arbitrage - https://www.dars.gov.et/
CSR Stock Alert: Halper Sadeh LLC is Investigating Whether Centerspace is Obtaining a Fair Price for its Shareholders - Business Wire
Passage Bio stock gains 1.01 percent as Remix deal advances - AD HOC NEWS
Passage Bio stock holds steady as investors eye recent trial and cash runway - AD HOC NEWS
Passage Bio stock holds steady as investors eye recent trial and cash runway - ad-hoc-news.de
Passage Bio stock holds steady as investors weigh gene therapy pipeline and recent losses - ad-hoc-news.de
Passage Bio Amends Remix Merger, Private Financing Terms - TipRanks
Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPE - TradingView
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
Remix deal would leave Passage Bio (NASDAQ: PASG) investors a small slice of the combined company - Stock Titan
Passage Bio stock reacts to reverse split as investors watch next steps - ad-hoc-news.de
Passage (PASG) Earnings Update: EPS Exceeds Its Estimate in the Latest Reading; Trading Move: Shares Fall 0.22% in the Current UpdateTech Earnings Analysis - vinanet.vn
Passage (PASG) Earnings Update: EPS Exceeds Its Estimate in the Latest Reading; Trading Move: Shares Fall 0.22% in the Current UpdateEarnings Season Outlook - dars.gov.et
GM1 Gangliosidosis Market Research Explores Growth Within A $0.95 Billion Opportunity - openPR.com
MDB Q2 2026 Earnings: EPS Beats Estimates by 10.06%, But Stock Slips 4.7%Consensus Miss Rate - dars.gov.et
Vestal Point Capital (PASG) filing shows no current Passage Bio share ownership - Stock Titan
Passage Bio | SCHEDULE 13G/A: Others - Moomoo
PASG Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2% Share GainSpecial Dividend Alert - vinanet.vn
Passage Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Passage Bio Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade
Passage Bio Q2 net loss narrows 16.67% to $7.82 million - Bitget
Passage Bio Q2 net loss narrows 16.67% to $7.82 million - Bitget
Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary - TradingView
PASG: Pending merger with Remix is vital as cash dwindles and operations wind down - TradingView
Passage Bio (PASG) outlines Q2 2026 loss, cash strain and Remix merger terms - Stock Titan
Passage Bio Inc expected to post a loss of $2.65 a shareEarnings Preview - TradingView
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CYBR.O Forecast — Price Prediction for 2026. Should I Buy CYBR.O? - Intellectia AI
Emerging Sub-Segments Transforming the Lysosomal Enzyme Market Landscape - openPR.com
REPX Q1 2026 Earnings: Deep EPS Miss Delivers -369.75% Surprise as Shares Gain 2.24%Revenue Breakdown Analysis - vinanet.vn
PASG Q2'26 Earnings: EPS estimate is (2.65) USD - TradingView
Passage Bio Inc. (PASG) Slips 3% as Shares Approach Key Support LevelRSI Overbought Alerts - vinanet.vn
Passage Bio Inc (PASG) Cash Flow - TradingKey
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Income Statement - tradingkey.com
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Passage Bio Inc (PASG) Balance Sheet - TradingKey
PASG|Passage Bio Inc|Price:4.570|Chg%:-0.370 - TradingKey
PASG|Passage Bio Inc|Price:4.940|Chg%:+0.040 - TradingKey
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Passage Bio Inc-Aktie (PASG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chou William | Officer |
Jan 09 '26 |
Proposed Sale |
18.43 |
4,076 |
75,120 |
0 |
| Chou William | PRESIDENT AND CEO |
Jan 08 '26 |
Sale |
18.44 |
4,076 |
75,159 |
6,524 |
| Borthwick Kathleen | CFO |
Jan 08 '26 |
Sale |
18.44 |
2,062 |
38,022 |
5,402 |
0.68%
3.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):